• 1. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 2. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 5. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylmethylamines

Comprehensive Overview of 4-[(pyrrolidin-1-yl)methyl]aniline hydrochloride (CAS No. 866956-98-1)

4-[(pyrrolidin-1-yl)methyl]aniline hydrochloride (CAS No. 866956-98-1) is a specialized organic compound widely utilized in pharmaceutical research and fine chemical synthesis. Its molecular structure features a pyrrolidine moiety linked to an aniline core via a methylene bridge, with a hydrochloride salt enhancing its stability. This compound has garnered significant attention due to its potential applications in drug discovery, particularly as a building block for kinase inhibitors and GPCR-targeted therapies, aligning with current trends in precision medicine.

In recent years, the demand for heterocyclic compounds like 4-[(pyrrolidin-1-yl)methyl]aniline hydrochloride has surged, driven by advancements in high-throughput screening and combinatorial chemistry. Researchers frequently search for its synthetic protocols, solubility data, and spectroscopic properties (e.g., NMR, HPLC), reflecting its role in optimizing lead compounds. The hydrochloride salt form improves aqueous solubility, a critical factor for bioavailability studies—a hot topic in pharmacokinetics discussions.

The compound’s structure-activity relationship (SAR) has been explored in modulating enzyme inhibition, particularly in oncology and neurology research. Its pyrrolidine-aniline scaffold mimics natural alkaloids, making it valuable for designing central nervous system (CNS) drugs. Notably, its logP and pKa values are often queried in databases, underscoring its relevance in ADMET prediction models—a key focus area for AI-driven drug design platforms.

From a synthetic chemistry perspective, 866956-98-1 serves as an intermediate for cross-coupling reactions (e.g., Buchwald-Hartwig amination) and reductive amination protocols. Lab-scale production typically involves protecting group strategies for the aniline nitrogen, followed by N-alkylation with pyrrolidine. These methods are frequently discussed in forums on green chemistry and atom economy, addressing sustainability concerns in modern synthesis.

Quality control of 4-[(pyrrolidin-1-yl)methyl]aniline hydrochloride requires rigorous chromatographic purity testing (≥95% by HPLC), with residual solvent analysis per ICH guidelines. Such specifications align with regulatory standards for pharmaceutical intermediates, a trending subject in GMP compliance audits. Additionally, its stability under accelerated conditions (40°C/75% RH) is often investigated to ensure shelf-life reliability.

Emerging applications include its use in proteolysis-targeting chimeras (PROTACs) and covalent inhibitor design, where its secondary amine functionality enables linker conjugation. These cutting-edge domains attract searches related to targeted protein degradation and E3 ligase recruitment, positioning the compound as a versatile tool in chemical biology.

In summary, CAS 866956-98-1 exemplifies the intersection of medicinal chemistry and process optimization. Its multifaceted utility—from hit-to-lead optimization to scale-up challenges—makes it a recurring subject in peer-reviewed journals and patent literature, particularly for teams working on small-molecule therapeutics and fragment-based drug discovery.

• 142335-64-6(4-[(pyrrolidin-1-yl)methyl]aniline)
• 916739-25-8(4-AMINO-N,N-DIBUTYL-BENZENEMETHANAMINE DIHYDROCHLORIDE)
• 91271-79-3(1-{4-[(pyrrolidin-1-yl)methyl]phenyl}methanamine)
• 866954-94-1(4-[(pyrrolidin-1-yl)methyl]aniline dihydrochloride)
• 64097-55-8(Benzenamine,N-phenyl-4-(1-pyrrolidinylmethyl)-)
• 29608-05-7(4-[(piperidin-1-yl)methyl]aniline)
• 263339-26-0(Benzenamine,4-(1-azetidinylmethyl)-)
• 183365-31-3(3-(Pyrrolidin-1-ylmethyl)aniline)
• 916739-30-5(4-(1-PIPERIDINYLMETHYL)-BENZENAMINE DIHYDROCHLORIDE)
• 91271-78-2(3-(Pyrrolidin-1-ylmethyl)phenylmethanamine)